




Oral & Poster Brochure

14 - 15 October 2021

www.ecth.org



ECTH 2021

European Congress on
Thrombosis and Haemostasis

Ghent, Belgium

14 - 15 October

Thursday 14 October 2021 - Day 1

Oral Communications

Chairs: Tilman Hackeng, The Netherlands & Timothée Bigot, France

- OP 1.1 13.45 - 13.57: Selective serotonin reuptake inhibitor use is associated with major bleeding during treatment with vitamin K antagonists: results of a cohort study, **Louise Burggraaf**, The Netherlands
- OP 1.2 13.57 - 14.09: Critical role of fibrin gamma-chain crosslinking by FXIIIa in preventing thrombus fragmentation and subsequent embolisation, **Cédric Duval**, United Kingdom
- OP 1.3 14.09 - 14.21: Platelet-specific acetyl-CoA carboxylase 1 deletion decreases phospholipid content and impairs platelet functions, **Marie Octave**, Belgium
- OP 1.4 14.21 - 14.33: TLR3 promotes venous thrombosis through endothelial cell activation, **Maria Najem**, France
- OP 1.5 14.33 - 14.45: Exploring new candidate mechanisms behind antithrombin deficiency in cases with unknown molecular basis: mosaicism and intronic profiles, **Pedro Garrido Rodríguez**, Spain

Oral Communications

Chairs: Johanna Gebhart, Austria & Pierre Morange, France

- OP 2.1 16.00 - 16.12: A hemostatic chemical compound against bleedings induced by direct oral anticoagulants., **Maximilien Desvages**, France
- OP 2.2 16.12 - 16.24: Presence and evolution of NET markers and DAMPS in critically ill COVID-19 patients, **Joram Huckriede**, The Netherlands
- OP 2.3 16.24 - 16.36: Global seroprevalence of pre-existing immunity against AAV serotypes in people with hemophilia A, **Sebastian Wolf**, Germany
- OP 2.4 16.36 - 16.48: Hypoxia augments proinflammatory activation of endothelial cells towards a prothrombotic phenotype, **Casper Uilsten-Wahlund**, Norway
- OP 2.5 16.48 - 17.00: Derivation of a predictive score for venous thromboembolism in women using combined oral contraceptives, **Pierre Suchon**, France

Science, Fast and Furious

Chairs: Sara Arcudi, Italy & Tom van de Berg, The Netherlands

- SFF1.1 17.00 - 17.15: Correlation of calibrated automated thrombogram parameters with clinical phenotype in a large cohort of patients with antithrombin deficiency carrying different SERPINC1 variants, **Carlos Bravo-Perez**, Spain
- SFF1.2 17.15 - 17.30: Inhibition of ADAMTS13 Rescues Acquired von Willebrand Syndrome in a Preclinical Left Ventricular Assist Device Animal Model, **Shannen J. Deconinck**, Belgium
- SFF1.3 17.30 - 17.45: S100A8/A9 levels are increased in COVID-19 patients and induce procoagulant platelets in a GPIIb/IIIa-dependent manner, **Martina Colicchia**, United Kingdom
- SFF1.4 17.45 - 18.00: Protease Nexin-1, a serpin participating in neutrophil recruitment through CD11a integrin regulation, **Céline Madjene**, France

Friday 15 October 2021 - Day 2

Oral Communications

Chairs: Sabine Eichinger, Austria & Zsuzsa Bagoly, Hungary

- OP 3.1 08.30 - 08.42: Genetic and clinical determinants of the outcome of immune tolerance induction in severe hemophilia A - preliminary results, **Ilja Oomen**, The Netherlands
- OP 3.2 08.42 - 08.54: The Extracellular Protease EpiP from *S. aureus* Triggers Blood Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1, **Vincenzo De Filippis**, Italy
- OP 3.3 08.54 - 09.06: Activation mechanism dependent surface exposure of cellular FXIII on platelets and platelet microparticles: immunofluorescence and immune electron microscopic study, **László Muszbek**, Hungary

- OP 3.4 09.06 - 09.18: Protein S Gla domain as theranostic for early vascular calcification, **Anouk Gentier**, Belgium
- OP 3.5 09.18 - 09.30: Remote history of venous thrombosis and the risk of venous thrombosis beyond the age of 70 years, **Huijie Wang**, The Netherlands

Oral Communications

Chair: Anouk Gentier, The Netherlands & Christelle Orlando, Belgium

- OP 4.1 10.45 - 10.57: COVID-19 associated coagulopathy in acute ischemic stroke patients treated with intravenous thrombolysis, **Zsuzsa Bagoly**, Hungary
- OP 4.2 10.57 - 11.09: Joint effect of multiple prothrombotic genotypes and mean platelet volume on the risk of incident venous thromboembolism, **Lisa Jakobsen**, Norway
- OP 4.3 11.09 - 11.21: Shear-induced platelet GPIIb/IIIa shedding under extracorporeal membrane oxygenation promotes platelet clearance independently from von Willebrand factor-GPIIb/IIIa interaction, **Annabelle Dupont**, France
- OP 4.4 11.21 - 11.33: Effects of dietary palmitate on blood lipid profile and calcification of aorta and aortic valve, **Nathalie Donis**, Belgium
- OP 4.5 11.33 - 11.45: Lower excess mortality in an anticoagulated population during the first wave of the COVID-19 pandemic in the Netherlands, **Qingui Chen**, The Netherlands

Oral Communications

Chairs: John-Bjarne Hansen, Norway & Sofia Melo, Belgium

- OP 5.1 13.00 - 13.12: A novel qualitative defect of VWF, **Tom van de Berg**, The Netherlands
- OP 5.2 13.12 - 13.24: Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura, **Laure De Waele**, Belgium
- OP 5.3 13.24 - 13.36: GPVI is a binding partner for pro-coagulant factor VIII on platelets, **Rohini Sekar**, France
- OP 5.4 13.36 - 13.48: Highly reactive juvenile platelets express higher levels of GPVI in a size-related manner, **Alicia Veninga**, The Netherlands
- OP 5.5 13.48 - 14.00: SARS-CoV2 associated venous thromboembolism - a one-year follow-up, **Alberto Maino**, Italy

Oral Communications

Chairs: Cédric Duval, United Kingdom & Thomas Vanassche, Belgium

- OP 6.1 14.15 - 14.27: Prosthetic valve bioactive surface coating to reduce the prevalence of thrombosis, **Cecile Oury**, Belgium
- OP 6.2 14.27 - 14.39: Venous Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis, **Rayna Anijs**, The Netherlands
- OP 6.3 14.39 - 14.51: Identification of two new ligands of the platelet CLEC-2 receptor, **Luis A. Moran**, United Kingdom
- OP 6.4 14.51 - 15.03: Elevated plasma levels of the complement activating enzyme MASP-2 are associated with risk of future incident venous thromboembolism, **Christabel Esi Damoah**, Norway
- OP 6.5 15.03 - 15.15: Role of Matrix Gla Protein in vascular calcification: hard chemistry for soft vessels, **Stijn Agten**, The Netherlands

BLEEDING

- P-001** Selection of immuno-dominant T cell epitopes from the repertoire of FVIII derived peptides presented on MHC class II, **Mariarosaria Miranda**, The Netherlands
- P-002** Genetic and non-genetic determinants of the outcome of immune tolerance induction in patients with hemophilia A and inhibitors - preliminary data of a systematic review, **Ilya Oomen**, The Netherlands
- P-003** Analysis of natural and recombinant missense variants involving Cysteine residues in factor XI: implications on folding, dimerization and function, **Carlos Bravo-Perez**, Spain
- P-004** Optimization of thrombin generation for hemophilia A, **Tom Van De Berg**, The Netherlands
- P-005** Induction of tolerance to therapeutic factor VIII in HA by modification with $\alpha 2,3$ sialic acid, **Eleonora Nardini**, The Netherlands
- P-006** Large-scale mapping of CD4 T-cell epitopes of recombinant full length FVIII in healthy individuals, **Valeria Porcheddu**, France
- P-007** Detection of endogenous FVIII variants in IPS derived vEC from Hemophilia A patients with null mutations., **Payal Chawla**, Germany
- P-008** Characterization of endothelial cell function in a patient with recurrent gastrointestinal bleeding using patient-derived endothelial colony forming cells, **Sebastiaan Laan**, The Netherlands
- P-009** Successful immunosuppressive therapy to eradicate an anti-factor V inhibitor responsible for two live-threatening hemorrhagic episodes, **Valérie Proulle**, France
- P-010** Impact of Heparin neutralization on Thrombin Generation Assay, **Marie Didembourg**, Belgium
- P-011** Tolerance induction towards FVIII in Haemophilia A patients through CAR-transduced Tregs, **Sarah Scatigna**, Germany
- P-013** Pooled real-world data of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of haemophilia A in Germany, Italy, and the United States, **Radovan Tomic**, Italy
- P-014** Effectiveness of FVIII-poor plasma-derived von Willebrand factor concentrate (WILFACTIN®) in patients with von Willebrand disease who underwent surgery, **Lucia Rugeri**, France
- P-016** Plasma thrombin generation in the presence of TIX-5 may contribute significantly to a prediction model for major bleeding in patients on VKA anticoagulant therapy, **Kees van 't Veer**, The Netherlands
- P-017** Structural variants in FXI deficiency: diagnosis, characterization by nanopore sequencing and mechanisms of formation., **Belén De La Morena-Barrio**, Spain
- P-018** Genotype-phenotype relations in hereditary hemorrhagic telangiectasia, **Zsuzsanna Bereczky**, Hungary
- P-020** The (im)possibility of diagnosing PAI-1-deficiency based on lab values in childhood, **Manon van der Meeren**, The Netherlands
- P-021** Role of next generation sequencing in identifying hemorrhagic disorders and its use in differential diagnosis, **Zsuzsanna Bereczky**, Hungary
- P-022** Social participation is reduced in type 3 Von Willebrand disease patients, **Eva K Kempers**, The Netherlands
- P-023** Discrepancies on VWF activity results between techniques due to genetic variants in the A1 domain: risk of misdiagnosis of VWD, **Fanny Lassalle**, France
- P-025** Safety of oral anticoagulation in Caucasian patients with FXI deficiency, **Carlos Bravo-Perez**, Spain

- P-026** A Canadian, multi-center, retrospective, non-interventional study of clinical outcomes from early use of N9-GP compared with previous treatment in patients with hemophilia B in a real-world setting, **Samer Matta**, Belgium
- P-027** MOREtogether: a dynamic video-based hemophilia community in Belgium, **Philip Maes**, Belgium
- P-028** Healthcare resource utilisation associated with the management of intracranial haemorrhage in patients receiving direct oral anticoagulants: a rapid literature review, **Sean Walsh**, United Kingdom
- P-029** Activated clotting time (ACT) can be used safely in patients treated with emicizumab, **Ladislav Capdevilla**, France
- P-030** Towards personalized care and patient empowerment: user perspectives on a personal health record in hemophilia care, **Martijn Brands**, The Netherlands
- P-031** Assessing the impact of COVID-19 on hemophilia patients aged ≥ 40 years and the HTC's that care for them: an observational cohort study from the ADVANCE group, **Cedric Hermans**, Belgium
- P-032** Healthcare resource utilisation associated with the management of major bleeding in patients receiving direct oral anticoagulants: a rapid literature review, **Sean Walsh**, United Kingdom
- P-033** The ethics of gene transfer for haemophilia: a systematic review, **Lieke Baas**, The Netherlands
- P-034** Safety profile of enoxaparin in noncritical hospitalized patients with COVID-19. Results of a retrospective multicenter study, **Javier Leal Martínez-Bujanda**, Spain
- P-035** Inhibitor to factor V in a patient with severe factor V deficiency after exposure to fresh frozen plasma, **Severine De Bruijn**, Belgium

CLOTTING

- P-037** An association of low-density lipoproteins and fibrinolysis in patients with severe aortic stenosis- valvular expression of fibrinolytic proteins, **Magdalena Kopytek**, Poland
- P-038** Socioeconomic status and risk of incident venous thromboembolism, **John-Bjarne Hansen**, Norway
- P-039** Identification of potential thrombotic biomarkers in advanced gastric cancer, **David Zaragoza Huesca**, Spain
- P-040** Genetic background of prothrombotic plasma fibrin clot properties in patients with acute pulmonary embolism and its association with post-PE syndrome, **Adrianna Klajmon**, Poland
- P-041** Molecular Interactions of Coagulation Factor XIII B Subunit, **Krisztina Penzes-Daku**, Hungary
- P-043** New procoagulant components from gastric cancer secretome, **David Zaragoza Huesca**, Spain
- P-044** Extracellular vesicles derived from activated platelets display an increased procoagulant activity and drive the production of TF by monocytes, **Eduarda Guerreiro**, Norway
- P-045** $\beta 2$ -Glycoprotein I ($\beta 2$ GpI) is a Fibrinogen Binding Protein, **Vincenzo De Filippis**, Italy
- P-046** Transcriptomic analysis of anti-tumour effect of prelatent anti-thrombin on glioblastoma multiforme cells, **Julia Peñas-Martínez**, Spain
- P-047** Identification of small interfering RNAs for allele-selective silencing of murine von Willebrand factor, **Yvonne Jongejan**, The Netherlands
- P-048** Simultaneous Assessment of DOACs Effects on Clot Formation and Fibrinolysis with the FibWave, **Jonathan Evrard**, Belgium

- P-049** Identification of Tumor-expressed MicroRNAs Associated with Venous Thrombosis in Colorectal Cancer, **Rayna Anijs**, The Netherlands
- P-051** Identification of structural variants in antithrombin deficiency using multiple ligation-dependent probe amplification, **Javier Corral de la Calle**, Spain
- P-052** Evaluation of sta-eca ii reagent for argatroban monitoring, **Thomas Flor**, The Netherlands
- P-053** Inter-laboratory variability of the standardized ETP-based APC resistance assay, **Laure Morimont**, Belgium
- P-054** Clot growth from a surface results in layers of fibrin with variation in lysisability., **Cornelis Kluff**, The Netherlands
- P-055** High throughput b-cell epitopes profiling, **Puneet Tomar**, Italy
- P-056** Transferability of the ETP-based APC resistance assay on the ST Genesia system, **Laure Morimont**, Belgium
- P-057** Influence of Tissue-Factor Pathway Inhibitor on Thrombin Generation Assay, **Marie Didembourg**, Belgium
- P-058** Molecular diagnosis and optimization of third generation sequencing methods in hemostasia and thrombosis: globalization of molecular analysis, **Jose Padilla Ruiz**, Spain
- P-059** Fragmentation of Histone H3 in severe COVID-19 patients, **Gerry AF Nicolaes**, The Netherlands
- P-060** Lupus anticoagulant-hypoprothrombinemia syndrome (lahs) associated to marginal zone lymphoma, **Andrés Peleteiro Raíndo**, Spain
- P-062** Association between cardiovascular risk factors and venous thrombosis in the elderly, **Huijie Wang**, The Netherlands
- P-063** Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRIP) study, a cohort based randomized controlled trial, **Louise Burggraaf**, The Netherlands
- P-064** Plasma levels of ADAMTS13, von Willebrand Factor/ADAMTS13 ratio and future risk of incident venous thromboembolism, **Magnus Sandvik Edvardsen**, Norway
- P-065** COVID-19 diagnosis and its impact on thrombotic risk in a cohort of consecutive patients hospitalized due to Acute Respiratory Distress Syndrome, **Andréa Coy Canguçu**, Brazil
- P-066** Risk factors and predictors for the occurrence of venous thromboembolism in patients with ischemic stroke: A systematic review, **Birgitte G. Tøndel**, Norway
- P-067** Changes in prescription pattern of oral anticoagulants and prognosis in incident non-valvular atrial fibrillation in the Netherlands, **Qingui Chen**, The Netherlands
- P-068** COVID-19-associated coagulopathy in pregnancy: a prospective, case-control study, **Zsuzsa Bagoly**, Hungary
- P-069** Body height and risk of venous thromboembolism in men versus women, **Sigrid Brækkan**, Norway
- P-070** Stability of oral anticoagulant treatment with vitamin K antagonists in COVID-19 patients, **Eleonora Camilleri**, The Netherlands
- P-071** Heart failure and subsequent thrombotic complications in a population with low baseline risk of thromboembolism: A nationwide cohort study, **Qingui Chen**, The Netherlands
- P-072** Evaluation of the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with SARS-CoV-2 infection, **Karen Claesen**, Belgium
- P-073** Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism, **John-Bjarne Hansen**, Norway
- P-075** Plasma levels of factor VIII and risk of future incident venous thromboembolism, **Ellen-Sofie Hansen**, Norway
- P-076** Predictive value of d-dimers in the clinical outcome of severe COVID19 patients: are we giving them too much credit?, **José Pedro Cidade**, Portugal

- P-077** Galectin-3-binding protein and risk of future venous thromboembolism, **Sigrid Brækkan**, Norway
- P-078** Impact of aortic valve replacement on the contact pathway, **María Eugenia De La Morena-Barrio**, Spain
- P-079** Pleiotropic influence of rosuvastatin on apolipoproteins and their association with coagulation factors: results from the START trial, **Eleonora Camilleri**, The Netherlands
- P-080** Plasma levels of adiponectin and risk of future incident venous thromboembolism, **Vânia Maris Morelli**, Norway
- P-081** Hypercoagulation detected by routine and global laboratory hemostasis assays in patients with infective endocarditis, **Ekaterina Koltsova**, Russia
- P-082** Short-term incidence of thrombotic complications in male-to-female transgender individuals, **Charlotte Steuwer**, The Netherlands
- P-083** Association of single nucleotide polymorphisms with major bleeding risk during Vitamin-K Antagonists treatment: a case-cohort study, **Eleonora Camilleri**, The Netherlands
- P-084** Thrombolysis in patients with pulmonary embolism and in-hospital cardiac arrest, **Caspar Epstein**, Sweden
- P-085** Clinical evolution of non-critical COVID-19 hospitalized patients treated with or without enoxaparin. Results of a retrospective multicenter study: HEPVID study, **Javier Leal Martínez-Bujanda**, Spain
- P-086** Predictors of Recurrence and Mortality Following First Venous Thromboembolism among Saudi Population: Single-Centre Cohort Study, **Alyah AlMoneef**, Saudi Arabia
- P-087** Quality of life and productivity of Hemophilia patients in Montenegro, **Enisa Zaric**, Montenegro
- P-088** Coagulation factors levels during and after anabolic androgenic steroid use: data from the HAARLEM study, **Eleonora Camilleri**, The Netherlands
- P-089** Investigations on Ethnic and Geographic Differences in Risk of Thrombophilia and its Implications in Disease Management, **Sarah Almukhaylid**, Saudi Arabia
- P-090** Cerebral Venous Sinus Thrombosis as first Manifestation of Primary Antiphospholipid Syndrome in a Patient with end-stage renal disease., **Roza Koliogeorgi**, Greece
- P-092** Critical upper limb ischemia, **Bouchra Karar**, Algeria

PLATELETS

- P-095** Plasma levels of platelet-derived microvesicles are associated with risk of future venous thromboembolism, **Omri Snir**, Norway
- P-096** Plasma and whole blood measurements of platelet (dys)function in HFpEF patients, **Giorgia D'Italia**, The Netherlands
- P-097** Role of platelet GARP in TGF beta activation, **Julie Bodart**, Belgium
- P-098** Acetyl-CoA carboxylase inhibition alters tubulin acetylation and aggregation in thrombin-stimulated platelets, **Laurence Piroton**, Belgium
- P-099** Differences in platelet proteomic profiles between healthy children and adults., **Andrei Kumar Garzon Dasgupta**, Russia
- P-100** An automated network biology approach to identify novel key players involved in platelet activation and inhibition, **Titus Lemmens**, The Netherlands
- P-101** Novel multimeric anti-GPVI nanobody and modelling reveals mechanism of GPVI clustering and activation, **Hilaire Yam Fung Cheung**, United Kingdom
- P-102** Combined antiplatelet therapy reduces the pro-inflammatory properties of activated platelets, **Alexandra Heinzmann**, The Netherlands
- P-103** Pathologic desialylation of platelets in ITP can be caused by platelet activation in circulation, **Olga I. An**, Russia

- P-104** Identification of a novel de novo SLFN14 variation associated with inherited thrombocytopenia: a case report, **Manal Ibrahim-Kosta**, France
- P-105** Software to make mathematical models of platelet regulation useful for biologists; allowing prediction, interpretation of experimental data, and hypothesis generation, **Fedor Balabin**, Russia
- P-108** Protein disulfide isomerase-A1 Regulates Intraplatelet NADPH Oxidase-1-Reactive Oxygen Species-Thromboxane A2-dependent Pathway In Response to GPVI-mediated Platelet Activation, **Kamil Przyborowski**, Poland
- P-109** Assessment of Platelet function and Inhibition by aspirin in patients Recovering from severe Infection (ASPIRIN-trial), **Moya Schutte**, The Netherlands
- P-110** Efficacy of SANDOSTATIN in the treatment of haemorrhagic angiodysplasia of the digestive tract in Glanzmann's disease, **Dominique Desprez**, France
- P-111** Platelet indices and coagulation markers in COVID-19 infected individuals, **Athanasia Agorasti**, Greece

VESSEL WALL

- P-112** Role of Syndecan-1 in Thoracic Aortic Aneurysm development, **Sara Zalghout**, France
- P-113** Epigenetic regulation of endothelial dysfunction in thromboembolic venous disease, **Marion Pilard**, France
- P-114** A rapid, sensitive and specific assay to measure TF activity based on chromogenic determination of thrombin generation, **Nadezhda Latysheva**, Norway
- P-115** Endothelial P2X7 promotes venous thromboembolism, **Estelle Olliver**, France
- P-116** The effects of platelet factor 4 (CXCL4) and its non-allelic variant (CXCL4L1) on the phenotype of human vascular smooth muscle cells in vitro, **Dawid Kaczor**, The Netherlands
- P-117** Comprehensive transcriptomic analysis of aorta and aortic valve in hypercholesterolemia, **Nathalie Donis**, Belgium
- P-118** Pathological vascular smooth muscle cell phenotype switching reduces expression of tissue factor pathway inhibitor, **Vanessa Bröker**, The Netherlands
- P-119** Cellular factor XIII in macrophage derived foam cells, **Laura Somodi**, Hungary
- P-120** Gender differences in the plasma concentration of the GAS6-TAM system in COVID-19 patients, **Gerry Nicolaes**, The Netherlands

14 - 15 October 2021
www.ecth.org